Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 9, 2018

Primary Completion Date

January 10, 2023

Study Completion Date

October 10, 2023

Conditions
Huntington Disease
Interventions
OTHER

Protocol Intervention Group

For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.

Trial Locations (1)

37232

Vanderbilt Medical Center, Nashville

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER

NCT03417583 - Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients | Biotech Hunter | Biotech Hunter